查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1584716

原料药药 CDMO 市场：依药物、产品、合成、工作流程、应用分类 - 2025-2030 年全球预测

Active Pharmaceutical Ingredients CDMO Market by Drug, Product, Synthesis, Workflow, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年原料原料药CDMO市场规模为1,148.5亿美元，预计2024年将达到1,264.2亿美元，复合年增长率为10.38%，预计2030年将达2,293.9亿美元。

活性药物原料药（API）CDMO（受託製造厂商）市场专注于药物开发和製造流程的外包，这对製药公司至关重要。由于 API 是药品的生物活性成分，因此 CDMO 市场由这些物质的合成、製程开发和大规模生产来定义。对 CDMO 的需求源自于製药公司简化业务、降低成本并专注于核心研发活动的需求。 原料药应用涵盖循环系统、肿瘤学和神经学等多种治疗领域，最终用途市场包括製药公司、生技公司和学名药製造商。目前，关键的成长要素包括生技药品和生物相似药的进步、慢性病的增加以及对个人化医疗的需求不断增长。新的商机在于转向更绿色的製造流程以及整合人工智慧以实现流程最佳化。然而，严格的监管要求、供应链中断和竞争加剧等挑战可能会抑制市场成长。与外包相关的品质问题和潜在的智慧财产权风险也是阻碍因素。为了应对这些挑战并利用机会，连续製造製程和奈米技术应用的创新可以提供重要的成长途径。此外，利用巨量资料分析和机器学习的数位转型提高流程效率也将开拓新的研发和业务发展领域。 API CDMO 市场呈现动态特征，研究合作和策略联盟成为获得市场占有率的关键策略。对研发和技术适应的持续投资可以帮助企业在不断变化的市场环境中提高竞争力。

主要市场统计
基准年[2023] 1148.5亿美元
预测年份 [2024] 1264.2亿美元
预测年份 [2030] 2293.9亿美元
复合年增长率（%） 10.38%

市场动态：快速发展的原料药药 CDMO 市场的关键市场洞察

原料原料药CDMO 市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 学名药需求增加，生物製药消费增加
    • 小分子的成长，原料药(API) 的复杂性增加
    • 对标靶癌症治疗和其他治疗的需求不断增长
  • 市场限制因素
    • 外包时的合规问题
  • 市场机会
    • 增加原料原料药CDMO 的研发投入
    • 抗癌药物研究进展
  • 市场挑战
    • 原料药CDMO 的严格监管合规要求

波特五力：驾驭原料药药 CDMO 市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解原料原料药CDMO 市场的外部影响

外部宏观环境因素在塑造原料原料药CDMO 市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解原料药药 CDMO 市场的竞争状况

药物原料药CDMO 市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵原料药药 CDMO 市场供应商的绩效评估

FPNV定位矩阵是评估原料原料药CDMO市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议 规划原料原料药CDMO 市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，原料药药 CDMO 市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 学名药需求增加，生物製药消费增加
      • 小分子的成长，活性药物成分 (API) 的复杂性增加
      • 对标靶癌症和其他医疗治疗的需求不断增长
    • 抑制因素
      • 外包时的合规问题
    • 机会
      • 增加原料药CDMO研发投入
      • 肿瘤药物研究持续变得更加复杂
    • 任务
      • API CDMO 的严格监管合规要求
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 依药物分類的原料药药 CDMO 市场

  • 非专利的
  • 创新的

第七章 药物原料药CDMO 市场：副产品

  • 抗体药物复合体
  • 非常强大的活性药物成分
  • 传统药物活性成分

第八章 合成原料药药 CDMO 市场

  • 生物技术
  • 合成

第 9 章原料药药 CDMO 市场：依工作流程

  • 临床
  • 商业的

第十章医药原料药CDMO市场：依应用分类

  • 心血管
  • 糖尿病
  • 青光眼
  • 荷尔蒙
  • 肿瘤学

第11章：北美和南美药物原料药CDMO市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太原料药药CDMO市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲/中东/非洲原料原料药CDMO市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • 5N Plus
  • AR Life Sciences Pvt. Ltd.
  • AbbVie Inc.
  • abcr GmbH
  • Biocon Limited
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Catalent, Inc.
  • Corden Pharma International GmbH
  • Curia Global, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Evonik Industries AG
  • IOL Chemicals and Pharmaceuticals Limited
  • Jungbunzlauer Suisse AG
  • Lonza Group Ltd.
  • Lupin Limited
  • Minafin Group
  • Mylan Inc.
  • Olon SpA
  • Piramal Group
  • PMC Group, Inc.
  • Polpharma SA
  • Recipharm AB
  • Samsung Biologics
  • SEQENS
  • Siegfried AG
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Tiefenbacher API+Ingredients GmbH & Co. KG
  • Xellia Pharmaceuticals ApS by Novo Holdings A/S
Product Code: MRR-575EAC9DD1AE

The Active Pharmaceutical Ingredients CDMO Market was valued at USD 114.85 billion in 2023, expected to reach USD 126.42 billion in 2024, and is projected to grow at a CAGR of 10.38%, to USD 229.39 billion by 2030.

The active pharmaceutical ingredients (API) CDMO (Contract Development and Manufacturing Organization) market focuses on the outsourcing of drug development and manufacturing processes which are crucial for pharmaceutical companies. APIs are the biologically active components in drugs; thus, the CDMO market is defined by the synthesis, process development, and large-scale production of these substances. The necessity for CDMOs arises from the need for pharmaceutical companies to streamline operations, reduce costs, and focus on core R&D activities. Applications of APIs span across various therapeutic areas such as cardiovascular, oncology, and neurology, with end-use markets including pharmaceutical companies, biotechnology firms, and generic drug manufacturers. Currently, key growth factors include advancements in biologics and biosimilars, increasing prevalence of chronic diseases, and the rising demand for personalized medicine. Emerging opportunities are grounded in the shifts towards greener manufacturing processes and artificial intelligence integration for process optimization. However, challenges such as stringent regulatory requirements, supply chain disruptions, and high competition may restrain market growth. Limitations also include the potential for quality concerns and IP risks associated with outsourcing. To address these challenges and leverage opportunities, innovations in continuous manufacturing processes and nanotechnology applications could present significant growth avenues. The digital transformation with the use of big data analytics and machine learning for enhanced process efficiencies also opens up new research and business development fields. The API CDMO market showcases a dynamic nature with collaborations and strategic partnerships emerging as key strategies to capture market share. With sustained investment in R&D and technology adaptation, companies can enhance their competitive edge in this evolving market landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 114.85 billion
Estimated Year [2024] USD 126.42 billion
Forecast Year [2030] USD 229.39 billion
CAGR (%) 10.38%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Active Pharmaceutical Ingredients CDMO Market

The Active Pharmaceutical Ingredients CDMO Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising demand for generic drugs and increasing consumption of biopharmaceuticals
    • Growth of small molecules, rising active pharmaceutical ingredient (API) complexity
    • Growing demand for targeted cancer and other medical treatments
  • Market Restraints
    • Issues associated with compliances while outsourcing
  • Market Opportunities
    • Increasing R&D investment for active pharmaceutical ingredients CDMO
    • Proliferating sophistication in oncology drug research
  • Market Challenges
    • Stringent regulatory compliance requirements for API CDMO

Porter's Five Forces: A Strategic Tool for Navigating the Active Pharmaceutical Ingredients CDMO Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Active Pharmaceutical Ingredients CDMO Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Active Pharmaceutical Ingredients CDMO Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Active Pharmaceutical Ingredients CDMO Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Active Pharmaceutical Ingredients CDMO Market

A detailed market share analysis in the Active Pharmaceutical Ingredients CDMO Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Active Pharmaceutical Ingredients CDMO Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Active Pharmaceutical Ingredients CDMO Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Active Pharmaceutical Ingredients CDMO Market

A strategic analysis of the Active Pharmaceutical Ingredients CDMO Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Active Pharmaceutical Ingredients CDMO Market, highlighting leading vendors and their innovative profiles. These include 5N Plus, A. R. Life Sciences Pvt. Ltd., AbbVie Inc., abcr GmbH, Biocon Limited, Boehringer Ingelheim International GmbH, Cambrex Corporation, Catalent, Inc., Corden Pharma International GmbH, Curia Global, Inc., Dr. Reddy's Laboratories Ltd., Evonik Industries AG, IOL Chemicals and Pharmaceuticals Limited, Jungbunzlauer Suisse AG, Lonza Group Ltd., Lupin Limited, Minafin Group, Mylan Inc., Olon S.p.A., Piramal Group, PMC Group, Inc., Polpharma SA, Recipharm AB, Samsung Biologics, SEQENS, Siegfried AG, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Tiefenbacher API + Ingredients GmbH & Co. KG, and Xellia Pharmaceuticals ApS by Novo Holdings A/S.

Market Segmentation & Coverage

This research report categorizes the Active Pharmaceutical Ingredients CDMO Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug, market is studied across Generics and Innovative.
  • Based on Product, market is studied across Antibody Drug Conjugate, Highly Potent Active Pharmaceutical Ingredient, and Traditional Active Pharmaceutical Ingredient.
  • Based on Synthesis, market is studied across Biotech and Synthetic.
  • Based on Workflow, market is studied across Clinical and Commercial.
  • Based on Application, market is studied across Cardiovascular, Diabetes, Glaucoma, Hormonal, and Oncology.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising demand for generic drugs and increasing consumption of biopharmaceuticals
      • 5.1.1.2. Growth of small molecules, rising active pharmaceutical ingredient (API) complexity
      • 5.1.1.3. Growing demand for targeted cancer and other medical treatments
    • 5.1.2. Restraints
      • 5.1.2.1. Issues associated with compliances while outsourcing
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing R&D investment for active pharmaceutical ingredients CDMO
      • 5.1.3.2. Proliferating sophistication in oncology drug research
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory compliance requirements for API CDMO
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Active Pharmaceutical Ingredients CDMO Market, by Drug

  • 6.1. Introduction
  • 6.2. Generics
  • 6.3. Innovative

7. Active Pharmaceutical Ingredients CDMO Market, by Product

  • 7.1. Introduction
  • 7.2. Antibody Drug Conjugate
  • 7.3. Highly Potent Active Pharmaceutical Ingredient
  • 7.4. Traditional Active Pharmaceutical Ingredient

8. Active Pharmaceutical Ingredients CDMO Market, by Synthesis

  • 8.1. Introduction
  • 8.2. Biotech
  • 8.3. Synthetic

9. Active Pharmaceutical Ingredients CDMO Market, by Workflow

  • 9.1. Introduction
  • 9.2. Clinical
  • 9.3. Commercial

10. Active Pharmaceutical Ingredients CDMO Market, by Application

  • 10.1. Introduction
  • 10.2. Cardiovascular
  • 10.3. Diabetes
  • 10.4. Glaucoma
  • 10.5. Hormonal
  • 10.6. Oncology

11. Americas Active Pharmaceutical Ingredients CDMO Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Active Pharmaceutical Ingredients CDMO Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Active Pharmaceutical Ingredients CDMO Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 5N Plus
  • 2. A. R. Life Sciences Pvt. Ltd.
  • 3. AbbVie Inc.
  • 4. abcr GmbH
  • 5. Biocon Limited
  • 6. Boehringer Ingelheim International GmbH
  • 7. Cambrex Corporation
  • 8. Catalent, Inc.
  • 9. Corden Pharma International GmbH
  • 10. Curia Global, Inc.
  • 11. Dr. Reddy's Laboratories Ltd.
  • 12. Evonik Industries AG
  • 13. IOL Chemicals and Pharmaceuticals Limited
  • 14. Jungbunzlauer Suisse AG
  • 15. Lonza Group Ltd.
  • 16. Lupin Limited
  • 17. Minafin Group
  • 18. Mylan Inc.
  • 19. Olon S.p.A.
  • 20. Piramal Group
  • 21. PMC Group, Inc.
  • 22. Polpharma SA
  • 23. Recipharm AB
  • 24. Samsung Biologics
  • 25. SEQENS
  • 26. Siegfried AG
  • 27. Sun Pharmaceutical Industries Limited
  • 28. Teva Pharmaceutical Industries Ltd.
  • 29. Tiefenbacher API + Ingredients GmbH & Co. KG
  • 30. Xellia Pharmaceuticals ApS by Novo Holdings A/S

LIST OF FIGURES

  • FIGURE 1. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET RESEARCH PROCESS
  • FIGURE 2. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET DYNAMICS
  • TABLE 7. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY GENERICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY INNOVATIVE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ANTIBODY DRUG CONJUGATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY TRADITIONAL ACTIVE PHARMACEUTICAL INGREDIENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY BIOTECH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CLINICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY HORMONAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 235. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 236. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET, FPNV POSITIONING MATRIX, 2023